Kovitz Investment Group Partners LLC Lowers Holdings in Kenvue Inc. (NYSE:KVUE)

Kovitz Investment Group Partners LLC reduced its position in shares of Kenvue Inc. (NYSE:KVUE) by 5.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,576 shares of the company’s stock after selling 3,228 shares during the period. Kovitz Investment Group Partners LLC’s holdings in Kenvue were worth $1,251,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Grove Bank & Trust grew its position in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Kenvue during the fourth quarter worth about $29,000. SRS Capital Advisors Inc. increased its position in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after purchasing an additional 571 shares during the last quarter. Fortitude Family Office LLC raised its stake in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc lifted its position in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after purchasing an additional 1,441 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 1.3 %

Shares of NYSE KVUE opened at $23.40 on Wednesday. The firm’s fifty day moving average is $23.06 and its 200 day moving average is $22.46. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company has a market cap of $44.90 billion, a price-to-earnings ratio of 44.15, a PEG ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.50%. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on KVUE. Canaccord Genuity Group increased their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. UBS Group reduced their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Piper Sandler lifted their price target on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th. Redburn Atlantic assumed coverage on Kenvue in a research report on Thursday, April 10th. They set a “neutral” rating and a $23.50 price objective on the stock. Finally, Citigroup boosted their target price on Kenvue from $21.00 to $22.00 and gave the stock a “neutral” rating in a research report on Monday, April 14th. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.